ClinicalTrials.gov record
Completed Phase 1 Interventional

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

ClinicalTrials.gov ID: NCT01026233

Public ClinicalTrials.gov record NCT01026233. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 8:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Intensive QT/QTc Study to Investigate the Effects of SGN-35 (Brentuximab Vedotin) on Cardiac Ventricular Repolarization in Patients With CD30-Positive Malignancies

Study identification

NCT ID
NCT01026233
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Seagen Inc.
Industry
Enrollment
52 participants

Conditions and interventions

Interventions

  • brentuximab vedotin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2009
Primary completion
Jul 31, 2010
Completion
Jul 31, 2011
Last update posted
Dec 11, 2014

2010 – 2011

United States locations

U.S. sites
8
U.S. states
7
U.S. cities
8
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294-3300
City of Hope National Medical Center Duarte California 91010
Stanford Cancer Center Stanford California 94305
University of Miami Hospital and Clinics, Miller School of Medicine Miami Florida 33136
Cardinal Bernardin Cancer Center / Loyola University Medical Center Maywood Illinois 60153
New York University Cancer Institute New York New York 10016
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
Baylor University Medical Center Dallas Texas 75246

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01026233, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 11, 2014 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01026233 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →